Among the various ␤-lactams, carbapenems are potent agents for the chemotherapy of infectious diseases caused by gram-negative rods, since they are quite stable against the ␤-lactamases produced by these organisms (5) . However, recently, the numbers of carbapenem-resistant clinical isolates which belong to the family Enterobacteriaceae or pseudomonads have been increasing in Japan (4, 7, 8, 19) , and some of them were found to produce a new metallo-␤-lactamase, IMP-1, which efficiently hydrolyzes carbapenems as well as broad-spectrum ␤-lactams (3, 12, 15, 16) . Moreover, IMP-1 is notable for its special character, in that it is hardly blocked by ␤-lactamase inhibitors such as clavulanate, sulbactam, and tazobactam (11) . Therefore, strains producing IMP-1 are difficult to control with ␤-lactams and related drugs in combination. Furthermore, we have reported that the metallo-␤-lactamase gene (bla IMP ) cassette of Serratia marcescens AK9373 is located in the space between the integrase gene (intI3) and the aminoglycoside acetyltransferase gene [aac(6Ј)-Ib] (1) and is transposed into other plasmids or the chromosomes of gramnegative bacteria by this integron element, which is mediated by large plasmids with wide host ranges. Int13 has been newly identified as the third class of integrase (14) , showing 60.9% amino acid sequence similarity to the reported integrase (IntI1) (2) . This finding warned of the further dissemination of the bla IMP gene cassette into various gram-negative rods. Quite recently, we also reported multifocal outbreaks of IMP-1-producing Pseudomonas aeruginosa isolates in Japan (17) . Hence, we have been directing special attention to the early recognition of metallo-␤-lactamase-producing clinical isolates. According to our previous studies of bla IMP -positive strains, the results of susceptibility tests were not enough for the identification of bla IMP -positive strains, because several clinical isolates carrying a cryptic bla IMP gene demonstrated low-level carbapenem resistance (MICs, Յ4 g/ml). However, the level of resistance to carbapenems in these strains might be elevated through enhanced expression of the bla IMP promoter in the presence of broad-spectrum cephems or carbapenems. Hence, early recognition of bla IMP -positive strains would be essential for the selection of appropriate antimicrobial agents for chemotherapy. In this study, therefore, ceftazidime-resistant gram-negative rods isolated from different hospitals in Japan were subjected to a PCR-aided rapid detection method with the bla IMP -specific primers.
MATERIALS AND METHODS
Bacterial strains. A total of 54 clinical isolates of gram-negative rods which demonstrated high-level resistance to ceftazidime (MICs, Ͼ128 g/ml) were subjected to PCR for detection of the bla IMP gene, since in our previous study all S. marcescens and P. aeruginosa strains that carry the bla IMP gene belonged to this group (3, 12, 17) . Thirty-three strains of P. aeruginosa and 1 strain of S. marcescens were provided by the Working Group on Antimicrobial Resistance Survey in Japan in 1994. Nine S. marcescens strains, five P. aeruginosa strains, and 1 Klebsiella pneumoniae strain were provided by Health Science Research Institute in 1995. Two P. aeruginosa strains were isolated at the Kyushu University Hospital in 1995, and two Alcaligenes xylosoxidans strains were isolated at the Nagoya University Hospital in 1994. One Pseudomonas putida strain was isolated at the Saga Medical School Hospital in 1994. All the bla IMP gene-positive strains, including 15 previously reported P. aeruginosa strains (17) and 5 S. marcescens strains (3, 12) , were subjected to PCR analyses to detect the intI3 and the aac(6Ј)-Ib genes.
Antimicrobial agents and susceptibility tests. The following antibiotics used in this study were provided by the indicated sources: amikacin, Bristol-Myers Squibb K.K., Tokyo, Japan; aztreonam, Eizai Co., Ltd., Tokyo, Japan; biapenem, Lederle (Japan), Ltd., Tokyo, Japan; BO2727 (9) (a new carbapenem) and imipenem, Banyu Pharmaceutical Co., Ltd., Tokyo, Japan; cefpirome, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan; cefoperazone-sulbactam, Pfizer Pharmaceutical Inc., Tokyo, Japan; cefsulodin, Takeda Chemical Industries, Ltd., Osaka, Japan; ceftazidime, Japan Glaxo Co., Tokyo, Japan; ciprofloxacin, Bayer Yakuhin, Ltd., Osaka, Japan; meropenem, Sumitomo Pharmaceutical Ltd., Osaka, Japan; moxalactam, Shionogi & Co., Ltd., Osaka, Japan; panipenem, Sankyo Co., Ltd., Tokyo, Japan; and piperacillin, Toyama Chemical Co., Ltd., Toyama, Japan.
Antimicrobial susceptibility testing was performed by the agar dilution method according to National Committee for Clinical Laboratory Standards document M7-A3 (10). Mueller-Hinton II agar and Mueller-Hinton II broth (BBL Microbiology Systems, Cockeysville, Md.) were used for susceptibility testing.
Design of oligonucleotide primers. The sequences and locations of the primers used in the PCR are listed in Fig. 1 . The bla IMP gene-and intI3 gene-specific primers were designed with OLIGO software, version 4.0 (Takara Shuzo Co., Ltd., Shiga, Japan). For the sequence of aac(6Ј)-Ib gene-specific primers, we referred to previously published data (13) .
PCR procedure. Template DNAs were prepared from each strain as described previously (18) . PCR amplification was performed in a 50-l volume with the GeneAmp PCR system 9600 (Perkin-Elmer Cetus, Norwalk, Conn.) thermal cycler. Reaction mixtures contained 1 M (each) primer, 200 M (each) deoxynucleoside triphosphate (Takara Shuzo Co., Ltd.), 1ϫ reaction buffer containing 1.5 mM MgCl 2 (Takara Shuzo Co., Ltd.), 2.5 U of TaKaRa Taq polymerase (Takara Shuzo Co., Ltd.), and approximately 25 ng of template DNA. After an initial denaturation step (2 min at 94ЊC), 30 cycles of amplification were performed, as follows: denaturation at 94ЊC for 1 min, annealing at 55ЊC for 1 min, and DNA extension at 72ЊC for 1.5 min. After agarose gel electrophoresis, the ethidium bromide-stained PCR products were visualized under UV light. In the amplification of the intI3 gene, the annealing step was carried out at 57ЊC. For more rapid and convenient template DNA extraction, the supernatant of a bacterial culture suspension boiled for 10 min was applied as described previously (6).
RESULTS AND DISCUSSION
For the preliminary study, 5 S. marcescens isolates (3, 12) and 15 P. aeruginosa isolates (17) which had been confirmed to carry the bla IMP gene by DNA hybridization analyses in our previous study were subjected to PCR analysis, and the bla IMPspecific fragments in all these isolates were amplified. Examples of the results of PCR analysis are presented in Fig. 2 . In contrast, no bla IMP -specific fragment was amplified in hybridization-negative S. marcescens and P. aeruginosa strains under the same experimental conditions. Thus, this PCR method was helpful for the rapid detection of the bla IMP gene. Then, 54 high-level ceftazidime-resistant clinical isolates (MICs, Ͼ128 g/ml) were screened by this method, and 9 P. aeruginosa isolates and 9 S. marcescens isolates were newly found to carry the bla IMP gene. The bla IMP gene was also detected in two A. xylosoxidans isolates, one P. putida isolate, and one K. pneumoniae isolate. The locations of the hospitals where bla IMPpositive strains were isolated are indicated in Fig. 3 . Indeed, the plasmid-mediated bla IMP gene was initially found in S. marcescens and P. aeruginosa isolates, but this is the first report of A. xylosoxidans and P. putida clinical isolates that carry the bla IMP gene. The bla IMP gene detected in these isolates might well be derived from S. marcescens or P. aeruginosa isolates by the help of transferable plasmids. The bla IMP gene was detected in both S. marcescens and K. pneumoniae strains from a hospital in Kanagawa. From a hospital in Aichi, the bla IMP gene was also detected in a P. aeruginosa strain and two A. xylosoxidans strains. Additionally, three bla IMP -positive strains of P. aeruginosa and one bla IMP -positive strain of S. marcescens were identified from a hospital in Kumamoto. In each hospital, plasmid-mediated intergenic transfer of the bla IMP gene was strongly suspected. Hence, we must face the facts that the bla IMP gene-bearing element has been dispersing among gramnegative organisms. The newly identified 22 bla IMP -positive strains showed consistent high-level resistance to almost all broad-spectrum cephems including ceftazidime and cefoperazone-sulbactam (MICs, Ն128 g/ml), but their levels of resistance to carbapenems were diverse ( Table 1) . Expression of the bla IMP gene might be cryptic or suppressed in the strains demonstrating low-level carbapenem resistance. In our previous work, cryptic bla IMP genes were also identified in several isolates of S. marcescens (3) and P. aeruginosa (17) . After long-term exposure to carbapenems, however, high-level carbapenem-resistant strains may emerge from the cryptic strains through elevated expression of the bla IMP gene because of mutations in its promoter region. Since antimicrobial susceptibility testing does not suffice for the early identification of the bla IMP -carrying strains, it is worthwhile to subject every clinical isolate demonstrating high-level resistance to ceftazidime and/or cefoperazone-sulbactam (MICs, Ն128 g/ml) to this PCR method for the detection of the bla IMP gene.
Although all the bla IMP -positive strains tested in this study demonstrated similar susceptibilities to five carbapenems, their susceptibilities to piperacillin and aztreonam did not parallel those to carbapenems. Aztreonam is notable for its relatively low MIC for IMP-1-producing isolates of S. marcescens. These findings may suggest the presence of alternative resistance mechanisms in high-level aztreonam-resistant strains such as MKCM43. Several bla IMP -positive strains tested in this study were still susceptible to ciprofloxacin and amikacin. Therefore, susceptibilities to new quinolones and aminoglycosides should be tested for clinical isolates which are suspected of carrying the bla IMP gene.
The sources of the bla IMP -positive strains were as follows. Six P. aeruginosa strains, eight S. marcescens strains, one P. putida strain, and one K. pneumoniae strain were isolated from urine samples. Two strains of A. xylosoxidans were from pharyngeal exudates. One P. aeruginosa strain was from bile. One strain of S. marcescens was from sputum. Broad-spectrum ␤-lactams are usually administered to inpatients through drip infusion, and they are mostly excreted in urine or bile without being dissolved or modified. Since these agents tend to be highly condensed in urine, bacteria surviving in the urinary tract must acquire high-level resistance to these agents. For this purpose, metallo-␤-lactamase production is of great benefit to these bacteria. Therefore, it is quite natural that the bla IMP -positive strains were often isolated from urine samples. When broad-spectrum cephems are administered, repeat identification and susceptibility testing of bacteria from urine samples, as well as the PCR analyses, would be helpful for the early recognition of bla IMP -positive strains. Moreover, a method for the direct detection of the bla IMP gene from the urine samples of patients infected with high-level cephem-resistant strains remains to be established.
Results of PCR detection of the intI3 gene and the aac(6Ј)-Ib gene are listed in positive A. xylosoxidans strains, 1 bla IMP -positive P. putida strain and 1 of bla IMP -positive K. pneumoniae strain. The aac(6Ј)-Ib gene was also amplified from 21 of the 24 bla IMPpositive P. aeruginosa strains, 9 of the 14 bla IMP -positive S. marcescens strains, and 1 bla IMP -positive K. pneumoniae strain. These results imply that the intI3 and aac(6Ј)-Ib genes are well conserved among these bla IMP -positive strains. Hence, these findings also suggest that the bla IMP gene cassettes have already been widely disseminated and will further disperse into various plasmids or chromosomes of gram-negative rods with the newly identified integron element.
In the present study, two different methods for the preparation of the DNA template were used. When the supernatant of a bacterial culture suspension boiled for 10 min was applied as a DNA template, we were unable to amplify the bla IMP gene in 1 of 24 bla IMP -positive P. aeruginosa strains and 4 of 14 S. marcescens strains. This might be due to the production of DNase or an inhibitor of Taq DNA polymerase, because we succeeded in amplifying the bla IMP gene when DNA templates prepared by a conventional method (18) were used. For the rapid and accurate detection of the bla IMP gene in clinical laboratories, more convenient methods for the preparation of DNA templates should be established.
In ordinary cases, it takes at least 3 days to receive the results of susceptibility tests from clinical laboratories, which might be too late to select appropriate antimicrobial agents for therapy. Therefore, the PCR-aided rapid detection method described here would provide a clue for rigorous infectious disease control. Moreover, the PCR detection method will contribute to the prevention of interhospital transfer of these bla IMP -carrying microorganisms.
